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Direct inhibitory effect of calcitriol on parathyroid function (sigmoidal
curve) in dialysis. The effect of intravenous calcitriol on parathyroid
function was evaluated in nine chronic hemodialysis patients with
secondary hyperparathyroidism. Two micrograms of calcitriol were
administered intravenously after dialysis thrice weekly for ten weeks.
Parathyroid function was assessed by inducing hypo- and hypercalce-
mia with low calcium (1.0 mEq/liter) and high calcium (4.0 mEq/liter)
dialyses before and after ten weeks of intravenous calcitriol therapy. To
avoid hypercalcemia during calcitriol administration, the dialysate
calcium was reduced to 2.5 mEq/liter. Parathyroid hormone (PTH)
values (pg/mI) from dialysis-induced hypo- and hypercalcemia were
plotted against serum ionized calcium, and the sigmoidal relationship
between PTH and calcium was evaluated. Basal PTH levels fell from
902 126 pg/mI to 466 152 pg/mI (P < 0.01) after therapy without a
significant change in the serum total calcium concentration. The ionized
calcium-PTH sigmoidal curve shifted to the left and downward after
calcitriol therapy. The maximal PTH response during hypocalcemia
decreased after calcitnol from 1661 485 pg/mI before calcitriol to 1031
280 pglml afterward (P < 0.05). The PTH level at maximal inhibition
due to hypercalcemia decreased from 281 76 pg/mI before calcitriol to
192 48 pg/mI afterward (P < 0.05). The slope of the sigmoidal curve
changed from —2125 487 to —1563 385 (P < 0.05). The set po:. .f
ionized calcium (4.60 .11 mgldl before vs. 4.44 .07 mg/dl after) did
not change significantly with calcitriol therapy. In summary, ten weeks
of intravenous calcitnol therapy decreased PTH secretion across a wide
range of serum ionized calcium concentrations, shifting the ionized
calcium-PTH sigmoidal curve toward normal (left and downward).
There were no significant changes in basal serum total calcium concen-
tration throughout the study. These results demonstrate a direct inhib-
itory effect of intravenous calcitriol on parathyroid function in dialysis
patients with secondary hyperparathyroidism.
The most common form of renal osteodystrophy present in
maintenance hemodialysis patients is osteitis fibrosa [1]. This is
characterized by increased bone formation and resorption, as
well as elevated parathyroid hormone (PTH) levels, and may be
present in early renal failure [2—4].
Calcitriol deficiency may contribute to the development and
maintenance of secondary hyperparathyroidism in dialysis pa-
tients. Calcitriol receptors are abundant in the parathyroid
gland and studies in parathyroid gland cell cultures have shown
mRNA coding for preproparathyroid hormone to be suppressed
by the addition of calcitriol to the cell cultures [5, 6]. Thus, in
addition to hypercalcemia induced by calcitriol, a direct inhib-
itory effect of calcitriol, independent of hypercalcemia, may be
important in the regulation of parathyroid gland activity [7].
Oral calcitriol therapy in dialysis patients with osteitis fibrosa
has been shown to decrease PTH levels [8]. This suppressant
effect of calcitriol on plasma PTH levels was assumed to be
secondary to the development of hypercalcemia. However,
recent data have demonstrated that the intravenous administra-
tion of calcitriol to dialysis patients with osteitis fibrosa mark-
edly reduced PTH levels [9]. These findings suggested the
possibility that calcitriol may directly inhibit PTH secretion.
However, most of the observed decrease in PTH levels oc-
curred at a time when the serum calcium level was increasing.
Thus, since the calcium-PTH relationship is not linear, the
possibility that an increase in the serum calcium concentration
may have been responsible for the PTH inhibition could not be
entirely excluded.
The concept of PTH secretion in relation to the set point of
calcium (defined as the calcium level at which maximal PTH
secretion is suppressed by 50%) has been developed as a
parameter of parathyroid gland sensitivity [10]. When parathy-
roid glands from patients with secondary hyperparathyroidism
were studied in vitro, an elevated set point of calcium for PTH
secretion was demonstrated [11, 12]. When the set point is
increased, a higher calcium concentration is required to inhibit
PTH secretion. We have shown that during a calcium free
dialysis some patients with osteitis fibrosa markedly increased
PTH secretion while the serum calcium remained greater than 9
mg/dl [13]. These observations suggest that the set point of
calcium may be abnormal in dialysis patients with osteitis
fibrosa. The possible role of calcitriol in the pathogenesis or
correction of the abnormal set point has not been previously
evaluated.
The aim of the present study was to evaluate in dialysis
patients with secondary hyperparathyroidism: a) whether a
direct effect of calcitriol on PTH secretion (independent of
hypercalcemia) is present; and b) the effect of intravenous
calcitriol on parathyroid function and the set point of calcium
for P1'H secretion.
Methods
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Nine stable patients on maintenance hemodialysis who had
never received calcitriol or vitamin D analogues were studied.
All patients had at least a 10-fold elevation of serum PTH,
serum aluminum levels less than 50 p.g/liter, and/or histological
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evidence of osteitis fibrosa with less than 5% stainable bone
aluminum. Patients were dialyzed 3-1/2 to 4 hours, three times
per week, and continued on aluminum-containing phosphate
binders throughout the study period. Dietary calcium remained
constant throughout the study.
Prior to administration of calcitriol, a low calcium dialysis
(dialysate calcium of 1.0 mEq/liter) was performed to induce
hypocalcemia. Hypocalcemia induced in this manner has been
shown to maximally stimulate PTH secretion [13]. Serum
calcium and PTH were sampled at the start of the low calcium
dialysis and every 30 minutes throughout the dialysis treatment.
The following week, a high calcium dialysis (dialysate calcium
of 4 mEq/liter) was performed to induce mild hypercalcemia
and maximally inhibit PTH secretion. Serum calcium and PTH
were obtained at baseline and every 30 minutes throughout the
dialysis, Serum chemistries, including phosphate, alkaline
phosphatase, total protein, albumin, and electrolytes were
obtained immediately before the low calcium dialysis.
Following the baseline studies, patients were treated with 2
j.g of intravenous calcitriol at the end of each dialysis for the
next ten weeks. During this time, the dialysate calcium was
reduced to 2.5 mEq/liter to prevent the development of hyper-
calcemia (14). Serum calcium and phosphate measurements
were obtained weekly prior to analysis. If the serum calcium
exceeded 10 mgldl, the calcitriol dosage was reduced. Only two
patients required a reduction of calcitriol to 1 g, after six and
eight weeks of therapy, respectively. Parathyroid hormone,
alkaline phosphatase, total protein, albumin, and electrolyte
determinations were made weekly. After ten weeks of calcitriol
therapy, the low and high calcium dialyses were repeated as
outlined above.
From the data obtained during dialysis-induced hypo- and
hypercalcemia, individual serum ionized calcium-PTH sigmoi-
dat curves were constructed for each patient before and after
calcitriol therapy. Composite serum calcium-PTH curves for
the group were compiled from the individual curves obtained
before and after treatment with calcitriol. The PTH values on
the composite curve (Fig. 2) at each calcium increment are the
mean for the group of PTH values obtained from each individ-
ual curve at that particular calcium concentration.
For analysis and interpretation of the serum calcium-PTH
curve the following terms are defined as follows: maximal PTH
stimulation is the highest FF11 level observed in response to
hypocalcemia; maximal PTH inhibition is the lowest PTH
concentration during suppression by hypercalcemia; the slope
of the sigmoidal curve is the PTH value at maximal PTH
stimulation minus the PTH value at maximal PTH inhibition
divided by the difference of the serum calcium concentration at
maximal PTH stimulation minus the serum calcium concentra-
tion at the maximal PTH inhibition; the set point of calcium is
the serum calcium concentration at which maximal PTH secre-
tion is reduced by 50%.
Anterior iliac crest bone biopsies were performed in eight
patients. Bone specimens were processed as previously de-
scribed and stained for aluminum by the method of Maloney et
al (15). Stainable trabecular bone aluminum was less than 5% in
all patients.
Intact parathyroid hormone was measured with an intact
hormone radioimmunoassay (Allegro, Nichols Institute, San
Juan Capistrano, California, USA) [16, 17]. Normal values are
10 to 65 pg/mI. Serum ionized calcium was evaluated using an
ICA 1 ionized calcium analyzer (Radiometer AIS,Copenhagen,
Denmark). Total serum calcium was determined by atomic
absorption spectrophotometry (Perkin-Elmer Corporation,
Norwalk, Connecticut, USA, model 5300). Serum phosphate,
alkaline phosphatase, total protein, albumin, and electrolytes
were measured by a Technicon SMA II autoanalyzer (Techni-
con Instruments Corporation, Tarrytown, New York, USA).
Serum aluminum was determined by fiameless atomic absorp-
tion spectrophotometry as previously described [18].
Informed consent was obtained from each patient in a proto-
cot approved by the Institutional Review Board of the Univer-
sity of Oklahoma Health Sciences Center and the Oklahoma
City Veterans Administration Medical Center.
Data was analyzed by Student's t-test for paired comparisons
and analysis of variance for repeated measures. Results are
expressed as mean SE.
Results
The study population consisted of nine maintenance hernodi-
alysis patients, of whom one was female. The mean age (± SE)
was 56.6 2.5 years and the length of time on dialysis was 33.7
7.5 months.
The mean baseline serum PTH level was markedly elevated
at 902 126 pg/mI. As shown in Figure 1, treatment with
calcitriol resulted in a gradual decrease of the high serum PTH
levels to 466 152 pg/mI by the end of ten weeks, P < 0.01.
This occurred even though the serum total calcium did not
change significantly (9.36 0.28 to 9.68 0.16 mg/dl). Other
laboratory findings were not altered by calcitriol therapy (Table
1). The mean serum albumin and total protein levels before and
after treatment were similar. The mean serum phosphate level
also remained unchanged and the mean serum alkaline phos-
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Fig. 1. Baseline PTH and total serum calcium levels during the ten
weeks of intravenous calcitriol therapy are shown. < 0.05 vs.
baseline; (5*) P < 0.01 vs. baseline.
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phatase level declined slightly. The serum bicarbonate concen-
tration increased during the study period (P < 0.05). No
significant change was seen in the baseline ionized calcium,
which was 4.49 0.11 mg/dl before calcitriol versus 4.40 0.06
mgldl after treatment.
Changes in the serum ionized calcium-PTH sigmoidal curve
before and after calcitriol therapy are shown in Figure 2. Before
calcitriol, the sigmoidal curve was shifted to the right and
upward when compared with normal patients [17]. After cal-
citriol, the serum PTH concentration was lower for each serum
calcium level throughout the entire range of serum calcium
concentrations; this is reflected by a shift of the curve down-
ward and to the left. Progressive hypocalcemia after maximal
PTH levels had been attained resulted in a decrease in the PTH
concentration. As shown in Figure 3, the maximal PTH re-
sponse induced during hypocalcemia decreased significantly
after calcitriol from 1661 485 to 1031 280 pg/mI, P < 0.05.
Also presented in Figure 3, the PTH level at maximal suppres-
sion during hypercalcemia decreased from 281 78 to 192 48
pg/mI, P <0.05. The slope of the sigmoidal curve decreased
significantly from —2125 487 to —1563 385, P < 0.05 (Fig.
4). The serum ionized calcium concentrations before and after
calcitriol at which maximal PTH stimulation (4.24 0.11 vs.
4.20 0.09 mgldl) and inhibition (4.96 .10 vs. 4.79 0.09
mg/dl) occurred were similar. The set point of calcium did not
change significantly after ten weeks of intravenous calcitriol
administration (Fig. 5). Thus, before calcitriol, the set point was
4.60 0.11 mgldl and after calcitriol 4.45 0.07 mg/dl.
Table 1. Biochemical data (mean SE) before and after calcitriol
therapy
Week I Week 10
Calcium mg/d/ 9.36 0.28 9.68 0.l6a
Albumin g//iter 41.5 1.3 40.5 0.9°
Total protein glliter 70.3 1.3 70.5 2.8a
P04 mg/d/ 7.86 0.95 7.81 0.43a
HCO3 mEqiliter 16.7 0.8 19.2 13b
Alk phos lU/liter 211.2 59.4 172.0 34•7a
a No significant difference between Weeks I and 10b P < 0.05compared to Week I
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Fig. 3. Changes before and after ca/citriol therapy in maximal stimu-
lated PTH levels during hypoca/cemia (A) and maximally inhibited
PTH levels by hypercalcemia (B) are shown.
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Fig. 4. The change in the slope of the sigmoidal calcium-PTH curve
before and after (---) ten weeks of intravenous calcitriol therapy is
presented.
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Fig. 2. The sigmoidal serum ionized ca/cium-PTH curve before (so/id
line) and after (dashed line) ten weeks of intravenous calcitriol therapy
is shown. The set point is represented by a solid square before and an
open square after calcitriol.
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Fig. 5. The set point of ca!cium (defined as the serum ca!cium !eve! at
which maxima! PTH secretion is reduced by 50%) before and after
ca/cUrio! is shown for each individua! patient.
Discussion
In the present study, ten weeks of thrice weekly intravenous
calcitnol significantly decreased PTH levels. Basal PTH levels
decreased in the absence of hypercalcemia. Furthermore, after
calcitriol therapy, the slope of the ionized calcium-PTH curve
decreased as a result of a reduction in the amount of PTH
produced during maximal stimulation and inhibition. These
findings strongly suggest a direct inhibitory effect of calcitriol
on PTH secretion. However, although there was a decrease in
the set point of calcium, it was not significant.
Slatopolsky et al have shown significant suppression of basal
PTH levels following intravenous calcitriol therapy in dialysis
patients with secondary hyperparathyroidism [9]. The authors
attributed some of the inhibitory effect of calcitriol on PTH
secretion to the increase in serum calcium observed during the
study period. However, their subjects showed a 20% decrease
in PTH levels prior to the increase in the serum calcium
concentration. Our results show that basal PTH levels declined
without a significant change in the serum calcium. Furthermore,
our results extend those of other clinical studies by demonstrat-
ing that after calcitriol, PTH levels were decreased throughout
a wide range of serum calcium concentrations [8, 9, 19]. Thus,
at both maximal stimulation and maximal inhibition, serum
PTH levels were lower after calcitriol therapy. Our patients'
serum phosphate levels were elevated, indicating noncompli-
ance with their prescribed phosphate binder. A greater reduc-
tion in PTH levels during calcitriol therapy might be seen in a
more compliant population.
Parathyroid glands ssess abundant calcitriol receptors, and
calcitriol is known to inhibit the synthesis of preproparathyroid
hormone [5, 6]. The use of intravenous calcitriol after each
hemodialysis treatment may lead to inhibition of the cellular
translation and transcription processes needed to produce the
increased amounts of PTH that characterize osteitis fibrosa. In
addition, calcitriol has been shown to increase cytosolic cal-
cium in parathyroid cell cultures; this effect may augment the
suppression in PTH secretion observed with calcitriol [20, 21].
The decrease in serum PTH observed in this study suggests that
the parathyroid glands do not escape the effects of calcitriol in
the 48 to 72 hours between doses. The biologic half-life of
calcitriol is six to ten hours [22]. Thus, calcitriol behaves as a
classic steroid hormone, with metabolic actions far outlasting
its plasma half-life. The clinical implication for the hemodialysis
patient with osteitis fibrosa is that two micrograms of calcitriol
administered intravenously thrice weekly may be sufficient to
significantly inhibit PTH secretion.
The level of PTH achieved during maximal stimulation of the
parathyroid gland with hypocalcemia decreased substantially
after ten weeks of intravenous calcitriol administration. Since
parathyroid gland mass correlates directly with maximal PTH
secretion [23], this suggests that calcitriol therapy leads to a
decrease in functional parathyroid gland mass. This could be
due to either a decrement in the amount of PTH produced by
each cell, a quantitative shift in the subset of cells from active
production and secretion to quiescence, or a combination of the
above mechanisms. After maximal PTH stimulation was
achieved during progressive hypocalcemia, there was a de-
crease in PTH levels. This phenomenon has been described
previously, and most likely is due to depletion of stored
hormone [241.
The inhibition of PTH secretion induced by hypercalcemia
was greater after calcitriol therapy as compared with pre-
treatment values. This may reflect a decrease in non-suppress-
ible parathyroid gland activity [25]. The calcium level at which
the parathyroid glands were maximally inhibited did not
change. The mechanisms underlying the decrease in PTH
secretion during both hyper- and hypocalcemia may be similar.
The slope of the sigmoidal curve of the ionized calcium-PTH
relationship decreased with calcitriol therapy. This change was
secondary to the decrease in maximally stimulated and inhib-
ited PTH secretion.
The set point of ionized calcium for PTH secretion did not
change with intravenous calcitriol therapy. An increase in the
set point leads to an increase in PTH secretion at a given
concentration of calcium; the opposite would occur if the set
point was decreased [26]. Our results indicate that calcitriol did
not affect the set point; however, it is possible that the lack of
effect may be due to the short duration of calcitriol therapy in
our study, or to the small number of patients studied. There was
a trend toward a decrease in the set point of calcium. In fact, the
mean set point of calcium would have decreased significantly if
we had removed from the study the only patient who demon-
strated an increase in the set point (Fig. 5).
Ionized calcium-PTH curves were recently reported in nor-
mal subjects by Brent et al, who used the same PTH assay to
study PTH secretion in response to EDTA and calcium infu-
sions [17]. They observed much smaller values for P1'H during
maximal stimulation (99 to 125 pg/mI) and maximal inhibition
(<10 pg/mI) than those noted in our study. Also, maximal
stimulation and inhibition of PTH secretion were achieved at
lower serum calcium concentrations in their normal patients
when compared with our subjects with secondary hyperpara-
thyroidism. In addition, these authors noted that the PTH
Dunlay et a!: Calcitriol and parathyroid function 1097
response to hypo- and hypercalcemia was not dependent on the
rate of change in the extracellular calcium concentration.
Our observations differ from the findings of Delmez et a!, who
reported a decrease in the set point of calcium for PTH
secretion after two weeks of intravenous calcitriol therapy [27].
However, in that study the set point was calculated as the
ionized calcium concentration at which baseline PTH values
were reduced by 50%. In the present study, the set point is
calculated according to the method of Brown et al, as the serum
calcium concentration at which maximal PTH secretion is
reduced by 50% [11].
In the past, calcitriol was thought to indirectly inhibit PTH
secretion by increasing the serum calcium concentration, bone
resorption [28, 29]. Recently, Yamamoto et al demonstrated
that changes in serum calcium concentrations regulate not only
the secretion, but also the biosynthesis, of PTH [30]. In addition
to the indirect effects of calcitriol, the present study strongly
suggests that intravenous calcitriol directly inhibits PTH secre-
tion. The effect of calcitriol on the parathyroid gland may be
maximized by intravenous administration of this hormone, as
compared with the oral route because of the higher serum
concentration of calcitriol achieved with the intravenous route.
Thus, for the same dose of calcitriol, fourfold higher serum
levels are achieved with an intravenous preparation, as com-
pared to the oral route [9]. Furthermore, calcitriol is hepatically
metabolized, and less drug may be available to target tissues
outside the gut if the drug is given orally [31].
There was a significant increase in serum bicarbonate con-
centration after calcitriol therapy. The reason for such incre-
ment is not apparent. Nevertheless, theoretically an increment
in serum bicarbonate may decrease serum ionized calcium;
thus, it may have played a role in the final serum ionized
calcium after calcitriol therapy.
In summary, ten weeks of thrice-weekly intravenous cal-
citriol therapy ameliorated secondary hyperparathyroidism in
our patients, by directly inhibiting PTH secretion. Calcitriol
produced a shift of the sigmoidal ionized-calcium PTH curve to
the left and downward. Although the set point of calcium did
not change, the slope of the calcium-PTH curve decreased. In
conclusion, intravenous calcitriol directly inhibits PTH secre-
tion and may be an effective treatment for secondary hyper-
parathyroidism in maintenance dialysis patients. Long-term
studies to evaluate the therapeutic benefit of intravenous cal-
citriol in dialysis patients with secondary hyperparathyroidism
are indicated.
Reprint requests to Francisco Liach, M.D.. Nephrology Division
(691/WIJIL) Wadsworth VA Medical Center, Wilshire and Sawtelle
Boulevards, Los Angeles, California 90073, USA.
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